MA35858B1 - Nouvelles formes et sels d'un inhibiteur de l'aldostérone synthase imidazole dihydropyrrolo [1,2-c] ou ou de l'inhibiteur de l'aromatase - Google Patents
Nouvelles formes et sels d'un inhibiteur de l'aldostérone synthase imidazole dihydropyrrolo [1,2-c] ou ou de l'inhibiteur de l'aromataseInfo
- Publication number
- MA35858B1 MA35858B1 MA37199A MA37199A MA35858B1 MA 35858 B1 MA35858 B1 MA 35858B1 MA 37199 A MA37199 A MA 37199A MA 37199 A MA37199 A MA 37199A MA 35858 B1 MA35858 B1 MA 35858B1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor
- salts
- aldosterone synthase
- dihydropyrrolo
- imidazole
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 5
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 title abstract 2
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 title abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 3
- 229940122815 Aromatase inhibitor Drugs 0.000 title 1
- 239000003886 aromatase inhibitor Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108010078554 Aromatase Proteins 0.000 abstract 1
- 102000014654 Aromatase Human genes 0.000 abstract 1
- 208000033054 Cushing disease Diseases 0.000 abstract 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 abstract 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne un sel de phosphate ou un sel de nitrate de 4- (r) -6,7-dihydro -5 h-pyrrolo [l, 2-c] imidazole -5-yl -3-fluoro-benzonitrile ayant la formule suivante: notamment sous forme cristalline, et les formes spécifiques de ces sels ainsi que des modes de réalisation de l'invention. Les sels et les formes de sels permettent le traitement prophylactique et/ou thérapeutique de l'aldostérone synthase et/ou des maladies ou troubles médiées de l'aromatase telle que la maladie de cushing.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261587280P | 2012-01-17 | 2012-01-17 | |
| PCT/US2013/021521 WO2013109514A1 (fr) | 2012-01-17 | 2013-01-15 | Nouvelles formes et sels d'un inhibiteur de l'aldostérone synthase imidazole dihydropyrrolo [1,2-c] ou ou de l'inhibiteur de l'aromatase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35858B1 true MA35858B1 (fr) | 2014-12-01 |
Family
ID=47604250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37199A MA35858B1 (fr) | 2012-01-17 | 2014-07-11 | Nouvelles formes et sels d'un inhibiteur de l'aldostérone synthase imidazole dihydropyrrolo [1,2-c] ou ou de l'inhibiteur de l'aromatase |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US9334276B2 (fr) |
| EP (1) | EP2804863B1 (fr) |
| JP (1) | JP5749410B2 (fr) |
| KR (2) | KR20140141687A (fr) |
| CN (1) | CN104039793B (fr) |
| AP (1) | AP2014007762A0 (fr) |
| AR (1) | AR089728A1 (fr) |
| AU (1) | AU2013209952B2 (fr) |
| BR (1) | BR112014017260A8 (fr) |
| CA (1) | CA2863339C (fr) |
| CL (1) | CL2014001863A1 (fr) |
| CO (1) | CO7000775A2 (fr) |
| CR (1) | CR20140345A (fr) |
| CU (1) | CU20140086A7 (fr) |
| CY (1) | CY1117914T1 (fr) |
| DK (1) | DK2804863T3 (fr) |
| EA (1) | EA026232B1 (fr) |
| ES (1) | ES2564143T3 (fr) |
| GT (1) | GT201400155A (fr) |
| HR (1) | HRP20160178T1 (fr) |
| HU (1) | HUE026984T2 (fr) |
| IL (1) | IL233541B (fr) |
| IN (1) | IN2014DN06781A (fr) |
| JO (1) | JO3137B1 (fr) |
| MA (1) | MA35858B1 (fr) |
| MX (1) | MX2014008686A (fr) |
| NZ (1) | NZ626277A (fr) |
| PE (1) | PE20142358A1 (fr) |
| PH (1) | PH12014501638A1 (fr) |
| PL (1) | PL2804863T3 (fr) |
| RS (1) | RS54589B1 (fr) |
| SG (1) | SG11201404061YA (fr) |
| SI (1) | SI2804863T1 (fr) |
| SM (1) | SMT201600083B (fr) |
| TN (1) | TN2014000256A1 (fr) |
| TW (1) | TWI609869B (fr) |
| UA (1) | UA114803C2 (fr) |
| UY (1) | UY34576A (fr) |
| WO (1) | WO2013109514A1 (fr) |
| ZA (1) | ZA201404314B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2523731B1 (fr) * | 2010-01-14 | 2018-10-24 | Novartis AG | Utilisation d'un agent modificateur d'hormone adrenale |
| EP2815749A1 (fr) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Forme solide de 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione ayant un réseau de diffraction de rayons X spécifique |
| PT3166596T (pt) | 2014-07-07 | 2018-10-19 | Novartis Ag | Formas farmacêuticas |
| KR102559242B1 (ko) | 2015-01-29 | 2023-07-25 | 리코다티 아게 | 축합된 이미다졸로 유도체의 제조 방법 |
| WO2016164476A2 (fr) * | 2015-04-06 | 2016-10-13 | Millendo Therapeutics, Inc. | Polythérapie pour le traitement de troubles liés à un excès de production de cortisol |
| SG11201903803UA (en) * | 2016-10-27 | 2019-05-30 | Damian Pharma Ag | Aldosterone synthase inhibitor |
| WO2018078049A1 (fr) * | 2016-10-27 | 2018-05-03 | Damian Pharma Ag | Inhibiteur de l'aldostérone synthase |
| WO2019211394A1 (fr) | 2018-05-03 | 2019-11-07 | Damian Pharma Ag | R-fadrozole destiné à être utilisé dans le traitement de l'aldostéronisme |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1315449A (en) * | 1918-11-15 | 1919-09-09 | Frank B Yingling | Shaper-feed. |
| US4617307A (en) * | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
| US5066656A (en) | 1989-11-01 | 1991-11-19 | Janssen Pharmaceutica N.V. | Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives |
| MTP1076B (en) * | 1990-01-12 | 1991-09-30 | Ciba Geigy Ag | Hemihydrate |
| WO1993015079A1 (fr) | 1992-01-27 | 1993-08-05 | Janssen Pharmaceutica N.V. | Derives de 1h-benzimidazole a substitutions pyrroloimidazolyle et imidazopyridinyle utilises comme inhibiteurs d'aromatase |
| ES2305520T3 (es) | 2002-11-18 | 2008-11-01 | Novartis Ag | Derivados de imidazo(1,5a)piridina y metodos para tratar enfermedades mediadas por aldosterona. |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| WO2008076862A2 (fr) | 2006-12-18 | 2008-06-26 | Novartis Ag | Composés organiques |
| EP2507234B1 (fr) | 2009-11-30 | 2014-03-12 | Novartis AG | Dérivés d'imidazole en tant qu'inhibiteurs de l'aldostérone synthase |
| EP2523731B1 (fr) * | 2010-01-14 | 2018-10-24 | Novartis AG | Utilisation d'un agent modificateur d'hormone adrenale |
-
2013
- 2013-01-15 AU AU2013209952A patent/AU2013209952B2/en active Active
- 2013-01-15 US US14/370,124 patent/US9334276B2/en active Active
- 2013-01-15 UY UY0001034576A patent/UY34576A/es not_active Application Discontinuation
- 2013-01-15 RS RS20160109A patent/RS54589B1/sr unknown
- 2013-01-15 AR ARP130100119A patent/AR089728A1/es unknown
- 2013-01-15 NZ NZ626277A patent/NZ626277A/en not_active IP Right Cessation
- 2013-01-15 UA UAA201406492A patent/UA114803C2/uk unknown
- 2013-01-15 SG SG11201404061YA patent/SG11201404061YA/en unknown
- 2013-01-15 PL PL13701194T patent/PL2804863T3/pl unknown
- 2013-01-15 CA CA2863339A patent/CA2863339C/fr active Active
- 2013-01-15 ES ES13701194.6T patent/ES2564143T3/es active Active
- 2013-01-15 KR KR20147030158A patent/KR20140141687A/ko not_active Ceased
- 2013-01-15 KR KR1020147016954A patent/KR20140093726A/ko not_active Ceased
- 2013-01-15 IN IN6781DEN2014 patent/IN2014DN06781A/en unknown
- 2013-01-15 HR HRP20160178T patent/HRP20160178T1/hr unknown
- 2013-01-15 SI SI201330142A patent/SI2804863T1/sl unknown
- 2013-01-15 EP EP13701194.6A patent/EP2804863B1/fr active Active
- 2013-01-15 EA EA201491374A patent/EA026232B1/ru not_active IP Right Cessation
- 2013-01-15 BR BR112014017260A patent/BR112014017260A8/pt not_active Application Discontinuation
- 2013-01-15 WO PCT/US2013/021521 patent/WO2013109514A1/fr not_active Ceased
- 2013-01-15 TW TW102101537A patent/TWI609869B/zh not_active IP Right Cessation
- 2013-01-15 DK DK13701194.6T patent/DK2804863T3/en active
- 2013-01-15 JP JP2014552375A patent/JP5749410B2/ja active Active
- 2013-01-15 CN CN201380005054.0A patent/CN104039793B/zh active Active
- 2013-01-15 PE PE2014001112A patent/PE20142358A1/es not_active Application Discontinuation
- 2013-01-15 AP AP2014007762A patent/AP2014007762A0/xx unknown
- 2013-01-15 JO JOP/2013/0014A patent/JO3137B1/ar active
- 2013-01-15 MX MX2014008686A patent/MX2014008686A/es unknown
- 2013-01-15 HU HUE13701194A patent/HUE026984T2/en unknown
-
2014
- 2014-06-11 ZA ZA2014/04314A patent/ZA201404314B/en unknown
- 2014-06-12 TN TNP2014000256A patent/TN2014000256A1/en unknown
- 2014-07-07 IL IL233541A patent/IL233541B/en active IP Right Grant
- 2014-07-08 CO CO14146898A patent/CO7000775A2/es unknown
- 2014-07-11 MA MA37199A patent/MA35858B1/fr unknown
- 2014-07-15 CL CL2014001863A patent/CL2014001863A1/es unknown
- 2014-07-15 CU CU2014000086A patent/CU20140086A7/es unknown
- 2014-07-17 CR CR20140345A patent/CR20140345A/es unknown
- 2014-07-17 PH PH12014501638A patent/PH12014501638A1/en unknown
- 2014-07-17 GT GT201400155A patent/GT201400155A/es unknown
-
2016
- 2016-02-09 US US15/018,953 patent/US20160176883A1/en not_active Abandoned
- 2016-02-26 CY CY20161100163T patent/CY1117914T1/el unknown
- 2016-03-23 SM SM201600083T patent/SMT201600083B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY187131A (en) | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same | |
| NZ630719A (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof | |
| EA201290244A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10 | |
| ECSP088906A (es) | PIRAZOLO 1,5-a PIRIMIDINAS | |
| UA107952C2 (uk) | ПОХІДНІ ІМІДАЗО[1,2-a]ПІРАЗИНУ І ЇХ ЗАСТОСУВАННЯ ДЛЯ ПРОФІЛАКТИКИ АБО ЛІКУВАННЯ НЕВРОЛОГІЧНИХ, ПСИХІАТРИЧНИХ І МЕТАБОЛІЧНИХ РОЗЛАДІВ І ЗАХВОРЮВАНЬ | |
| EA201171306A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-α]ПИРИДИНА, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКРЕТАЗЫ | |
| MX2012000513A (es) | Compuestos pirazolo[1,5-a]pirimidina substituidos como inhibidores de trk cinasa. | |
| PH12014501638A1 (en) | New forms and salts of a dihydropyrrolo [1,2-c] imidazolyl aldosterone synthase or aromatase inhibitor | |
| SG10201900514RA (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors | |
| GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
| BRPI1012108B8 (pt) | composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico | |
| GB201104267D0 (en) | Pyrrolopyridineamino derivatives | |
| IN2014DN08886A (fr) | ||
| TN2013000325A1 (en) | (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases | |
| MY150747A (en) | Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer | |
| GEP20166481B (en) | (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors | |
| MX2015000336A (es) | Inhibidores de la enzima fosfodiesterasa 10. | |
| WO2010039825A3 (fr) | Composés d'imidazo[1,2a]pyridine en tant que tyrosine kinase de récepteur | |
| EA201490164A1 (ru) | Твердые формы и соли производных тетрагидропиридопиримидина | |
| TN2010000530A1 (en) | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same | |
| HK1173146A (en) | Kinase inhibitors, prodrug forms thereof and their use in therapy |